Lipocine amends filing to detail Grissinger's compensation committee role
The company's August 21 amendment clarifies that director Michael Grissinger joined the Compensation Committee on August 18, 2026, with added annual pay for the role.
Lipocine Inc. filed a Form 8-K/A on August 21, 2026 to amend an earlier report. The original filing, dated August 3, 2026, disclosed that Lipocine had appointed Michael Grissinger to its Board.1 The amendment adds detail on Grissinger's placement on the Board's Compensation Committee.1
According to the filing, the Board took action on August 18, 2026 to add Grissinger to the Compensation Committee.1 For this role, he is entitled to an added $7,500 annually.1
The filing was signed by Mahesh V. Patel, President and Chief Executive Officer of Lipocine Inc., on August 21, 2026.1 Lipocine is registered under the ticker LPCN on the Nasdaq Stock Market.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.